184 related articles for article (PubMed ID: 24966967)
1. Human epidermal growth factor receptor 2 expression in urothelial carcinoma of the renal pelvis: correlation with clinicopathologic parameters.
Ehsani L; Osunkoya AO
Int J Clin Exp Pathol; 2014; 7(5):2544-50. PubMed ID: 24966967
[TBL] [Abstract][Full Text] [Related]
2. Human epidermal growth factor receptor 2 expression in micropapillary urothelial carcinoma of the bladder: an analysis of 27 cases.
Goodman AL; Osunkoya AO
Hum Pathol; 2016 Nov; 57():160-164. PubMed ID: 27476777
[TBL] [Abstract][Full Text] [Related]
3. Human Epidermal Growth Factor Receptor 2 Overexpression in Micropapillary and Other Variants of Urothelial Carcinoma.
Behzatoğlu K; Yörükoğlu K; Demir H; Bal N
Eur Urol Focus; 2018 Apr; 4(3):399-404. PubMed ID: 28753766
[TBL] [Abstract][Full Text] [Related]
4. Correlation of human epidermal growth factor receptor 2 expression with clinicopathological characteristics and prognosis in gastric cancer.
He C; Bian XY; Ni XZ; Shen DP; Shen YY; Liu H; Shen ZY; Liu Q
World J Gastroenterol; 2013; 19(14):2171-8. PubMed ID: 23599643
[TBL] [Abstract][Full Text] [Related]
5. HER2 Status in Molecular Subtypes of Urothelial Carcinoma of the Renal Pelvis and Ureter.
Yorozu T; Sato S; Kimura T; Iwatani K; Onuma H; Yanagisawa T; Miki J; Egawa S; Ikegami M; Takahashi H
Clin Genitourin Cancer; 2020 Aug; 18(4):e443-e449. PubMed ID: 31983622
[TBL] [Abstract][Full Text] [Related]
6. HER2 protein overexpression and gene amplification in upper urinary tract urothelial carcinoma-an analysis of 171 patients.
Sasaki Y; Sasaki T; Kawai T; Morikawa T; Matsusaka K; Kunita A; Kume H; Aoki I; Homma Y; Fukayama M
Int J Clin Exp Pathol; 2014; 7(2):699-708. PubMed ID: 24551292
[TBL] [Abstract][Full Text] [Related]
7. Urothelial carcinoma of the renal pelvis: a clinicopathologic study of 130 cases.
Olgac S; Mazumdar M; Dalbagni G; Reuter VE
Am J Surg Pathol; 2004 Dec; 28(12):1545-52. PubMed ID: 15577672
[TBL] [Abstract][Full Text] [Related]
8. High-grade urothelial carcinoma of the renal pelvis: clinicopathologic study of 108 cases with emphasis on unusual morphologic variants.
Perez-Montiel D; Wakely PE; Hes O; Michal M; Suster S
Mod Pathol; 2006 Apr; 19(4):494-503. PubMed ID: 16474378
[TBL] [Abstract][Full Text] [Related]
9. Invasive high-grade urothelial carcinoma of the bladder, renal pelvis, ureter, and prostatic urethra arising in a background of urothelial carcinoma with an inverted growth pattern: a contemporary clinicopathological analysis of 91 cases.
Gutierrez CM; Alemozaffar M; Osunkoya AO
Hum Pathol; 2019 Oct; 92():18-24. PubMed ID: 31351154
[TBL] [Abstract][Full Text] [Related]
10. HER2 immunohistochemistry staining positivity is strongly predictive of tumor response to neoadjuvant chemotherapy in HER2 positive breast cancer.
Zhao J; Krishnamurti U; Zhang C; Meisel J; Wei Z; Suo A; Aneja R; Li Z; Li X
Pathol Res Pract; 2020 Nov; 216(11):153155. PubMed ID: 32871536
[TBL] [Abstract][Full Text] [Related]
11. Overexpression of laminin-5 gamma2 chain and its prognostic significance in urothelial carcinoma of urinary bladder: association with expression of cyclooxygenase 2, epidermal growth factor receptor [corrected] and human epidermal growth factor receptor [corrected] 2.
Kiyoshima K; Oda Y; Kinukawa N; Naito S; Tsuneyoshi M
Hum Pathol; 2005 May; 36(5):522-30. PubMed ID: 15948119
[TBL] [Abstract][Full Text] [Related]
12. Prognostic value of PIK3CA mutation status, PTEN and androgen receptor expression for metastasis-free survival in HER2-positive breast cancer patients treated with trastuzumab in adjuvant setting.
Adamczyk A; Niemiec J; Janecka A; Harazin-Lechowska A; Ambicka A; Grela-Wojewoda A; Domagała-Haduch M; Cedrych I; Majchrzyk K; Kruczak A; Ryś J; Jakubowicz J
Pol J Pathol; 2015 Jun; 66(2):133-41. PubMed ID: 26247526
[TBL] [Abstract][Full Text] [Related]
13. Nested variant of urothelial carcinoma of the renal pelvis.
Lau SK
Pathol Res Pract; 2009; 205(7):508-12. PubMed ID: 19171439
[TBL] [Abstract][Full Text] [Related]
14. Polypoid urothelial tumor with inverted growth pattern in the renal pelvis: morphologic and molecular characteristics of a unique diagnostic entity.
Wobker SE; Zhong M; Epstein JI
Hum Pathol; 2017 Jan; 59():26-33. PubMed ID: 27574810
[TBL] [Abstract][Full Text] [Related]
15. Human epidermal growth factor receptor 2 expression in mixed gastric carcinoma.
Wang YK; Chen Z; Yun T; Li CY; Jiang B; Lv XX; Chu GH; Wang SN; Yan H; Shi LF
World J Gastroenterol; 2015 Apr; 21(15):4680-7. PubMed ID: 25914479
[TBL] [Abstract][Full Text] [Related]
16. Insulin-like growth factor-1 receptor expression in upper tract urothelial carcinoma.
Eich ML; Tregnago AC; Faraj SF; Palsgrove DN; Fujita K; Bezerra SM; Munari E; Sharma R; Chaux A; Netto GJ
Virchows Arch; 2019 Jan; 474(1):21-27. PubMed ID: 30338346
[TBL] [Abstract][Full Text] [Related]
17. Assessment of human epidermal growth factor receptor 2 status in urothelial carcinoma of the upper urinary tract: a study using dual-color in situ hybridization and immunohistochemistry.
Vershasselt-Crinquette M; Colin P; Ouzzane A; Gnemmi V; Robin YM; Aubert S; Villers A; Leroy X
Appl Immunohistochem Mol Morphol; 2012 Jul; 20(4):363-6. PubMed ID: 22495372
[TBL] [Abstract][Full Text] [Related]
18. GATA3 immunohistochemistry in urothelial carcinoma of the upper urinary tract as a urothelial marker and a prognosticator.
Inoue S; Mizushima T; Fujita K; Meliti A; Ide H; Yamaguchi S; Fushimi H; Netto GJ; Nonomura N; Miyamoto H
Hum Pathol; 2017 Jun; 64():83-90. PubMed ID: 28428106
[TBL] [Abstract][Full Text] [Related]
19. HER2/neu gene amplification and protein overexpression in G3 pT2 transitional cell carcinoma of the bladder: a role for anti-HER2 therapy?
Latif Z; Watters AD; Dunn I; Grigor K; Underwood MA; Bartlett JM
Eur J Cancer; 2004 Jan; 40(1):56-63. PubMed ID: 14687790
[TBL] [Abstract][Full Text] [Related]
20. Tumor-Infiltrating Lymphocytes and Associations With Pathological Complete Response and Event-Free Survival in HER2-Positive Early-Stage Breast Cancer Treated With Lapatinib and Trastuzumab: A Secondary Analysis of the NeoALTTO Trial.
Salgado R; Denkert C; Campbell C; Savas P; Nuciforo P; Aura C; de Azambuja E; Eidtmann H; Ellis CE; Baselga J; Piccart-Gebhart MJ; Michiels S; Bradbury I; Sotiriou C; Loi S
JAMA Oncol; 2015 Jul; 1(4):448-54. PubMed ID: 26181252
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
